Vacuum-assisted excision: a safe minimally invasive option for benign phyllodes tumor diagnosis and treatment-a systematic review and meta-analysis.

Synopsis: This is a systematic review and meta-analysis comparing surgical excision with percutaneous ultrasound-guided vacuum-assisted excision (US-VAE) for the treatment of benign phyllodes tumor (PT) using local recurrence (LR) as the endpoint. Objective: To determine the frequency of local recurrence (LR) of benign phyllodes tumor (PT) after ultrasound-guided vacuum-assisted excision (US-VAE) compared to the frequency of LR after surgical excision. Method: A systematic review and meta-analysis [following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) standard] was conducted by comparing LR in women older than 18 years treated for benign PT by US-VAE compared with local surgical excision with at least 12 months of follow-up. Studies were retrieved from PubMed, Scopus, Web of Science, and Embase. The pooled effect measure used was the odds ratio (OR) of recurrence. Results: Five comparative prospective or retrospective observational studies published between January 1, 1992, and January 10, 2022, comparing surgical excision with percutaneous US-VAE for LR of benign PT met the selection criteria. Four were retrospective observational cohorts, and one was a prospective observational cohort. A total of 778 women were followed up. Of them, 439 (56.4%) underwent local surgical excision, and 339 (43.6%) patients had US-VAE. The median age of patients in the five studies ranged from 33.7 to 39 years; the median size ranged from 1.5 cm to 3.0 cm, and the median follow-up ranged from 12 months to 46.6 months. The needle gauge ranged from 7G to 11G. LR rates were not statically significant between US-VAE and surgical excision (41 of 339 versus 34 of 439; OR 1.3; p = 0.29). Conclusion: This meta-analysis suggests that using US-VAE for the removal of benign PT does not increase local regional recurrence and is a safe minimally invasive therapeutic option. Systematic review registration: https://www.crd.york.ac.uk/prospero/, identifier CRD42022309782.

Potential role of vacuum-assisted procedures in resecting breast cancers and highlighting selection criteria to support future trials.

Purpose: The purpose of this study was to evaluate the role of vacuum-assisted biopsy (VAB) in resecting breast cancers. Methods: Retrospective database analysis of 116 cancers [both invasive breast cancers (IC) and ductal carcinoma in situ (DCIS)] diagnosed by VAB submitted to standard surgical treatment with complete histological data from VAB and surgery. Excision following VAB was defined as complete resection (CR) if there was no residual tumor in the surgical specimen, minimal residual disease (MRD) if residual tumor ≤ 3 mm, gross residual disease (GRD) if residual tumor > 3 mm, and upgrade from DCIS on VAB to IC. CR and MRD were combined as potentially resected percutaneously (PRP). GRD and those with upgrade to IC were determined not eligible for percutaneous resection (NPR). Factors predictive of PRP were evaluated. Results: Mean age was 55.6 years (20-91; SD: 12,27). CR was seen in 29 of 116 cases (25%), MRD in 18 of 116 cases (15.5%), GRD in 64 of 116 cases (55.2%), and five of 116 cases (4.3%) were upgraded from DCIS to IC, and those groups combined represented 47 cases of PRP (40.5%) and 69 (59,5%) of NPR. For 77 tumors ≤ 10 mm, 45 (58.5%) were PRP. Multivariate analysis reveals significance for enlarged VAB (EVAB) (p = 0.008, OR: 4.4, 95% CI), low/intermediate nuclear grade (p < 0.001, OR: 12.5, 95% CI) and final tumor size (T) ≤ 10 mm (p = 0.001, OR: 50.1, 95% CI) for PRP. Conclusions: This study showed that lesions completely excised with VAB that were cancer could have been treated with VAB rather than surgery but tumor selection in terms of subtype and size is important.

Diagnostic underestimation of atypical ductal hyperplasia and ductal carcinoma in situ at percutaneous core needle and vacuum-assisted biopsies of the breast in a Brazilian reference institution.

OBJECTIVE: To determine the rates of diagnostic underestimation at stereotactic percutaneous core needle biopsies (CNB) and vacuum-assisted biopsies (VABB) of nonpalpable breast lesions, with histopathological results of atypical ductal hyperplasia (ADH) or ductal carcinoma in situ (DCIS) subsequently submitted to surgical excision. As a secondary objective, the frequency of ADH and DCIS was determined for the cases submitted to biopsy. MATERIALS AND METHODS: Retrospective review of 40 cases with diagnosis of ADH or DCIS on the basis of biopsies performed between February 2011 and July 2013, subsequently submitted to surgery, whose histopathological reports were available in the internal information system. Biopsy results were compared with those observed at surgery and the underestimation rate was calculated by means of specific mathematical equations. RESULTS: The underestimation rate at CNB was 50% for ADH and 28.57% for DCIS, and at VABB it was 25% for ADH and 14.28% for DCIS. ADH represented 10.25% of all cases undergoing biopsy, whereas DCIS accounted for 23.91%. CONCLUSION: The diagnostic underestimation rate at CNB is two times the rate at VABB. Certainty that the target has been achieved is not the sole determining factor for a reliable diagnosis. Removal of more than 50% of the target lesion should further reduce the risk of underestimation.

OBJETIVO: Determinar o grau de subestimação diagnóstica de biópsias mamárias percutâneas estereotáxicas por agulha grossa (core biopsy) e assistidas a vácuo (mamotomia) em lesões não palpáveis, com resultados histopatológico de hiperplasia ductal atípica (HDA) ou carcinoma ductal in situ (CDIS) e que foram submetidas a exérese cirúrgica posteriormente. Como objetivo secundário, atribuiu-se a frequência de HDA e CDIS nos casos biopsiados. MATERIAIS E MÉTODOS: Foram revisados, retrospectivamente, 40 casos biopsiados com diagnóstico de HDA ou CDIS, entre fevereiro de 2011 e julho de 2013, e que posteriormente foram submetidos a cirurgia, cujo laudo histopatológico estava registrado no sistema interno de informações. Os resultados das biópsias foram comparados aos da cirurgia e a taxa de subestimação foi calculada de acordo com equações matemáticas específicas. RESULTADOS: A taxa de subestimação diagnóstica da core biopsy foi 50% para HDA e 28,57% para CDIS, e da mamotomia foi 25% para HDA e 14,28% para CDIS. As HDAs representaram 10,25% do total de casos biopsiados, enquanto 23,91% foram CDIS. CONCLUSÃO: A taxa de subestimação diagnóstica é cerca de duas vezes maior na core biopsy em relação à mamotomia. A certeza do alvo atingido não é o único determinante para um diagnóstico preciso. Remover mais que 50% da lesão alvo poderá diminuir o risco de subestimação diagnóstica.

Diagnostic underestimation of atypical ductal hyperplasia and ductal carcinoma in situ at percutaneous core needle and vacuum-assisted biopsies of the breast in a Brazilian reference institution / Subestimação diagnóstica das biópsias mamárias percutâneas por agulha grossa e assistidas a vácuo na hiperplasia ductal atípica e no carcinoma ductal in situ em instituição brasileira de referência

Abstract Objective: To determine the rates of diagnostic underestimation at stereotactic percutaneous core needle biopsies (CNB) and vacuum-assisted biopsies (VABB) of nonpalpable breast lesions, with histopathological results of atypical ductal hyperplasia (ADH) or ductal carcinoma in situ (DCIS) subsequently submitted to surgical excision. As a secondary objective, the frequency of ADH and DCIS was determined for the cases submitted to biopsy. Materials and Methods: Retrospective review of 40 cases with diagnosis of ADH or DCIS on the basis of biopsies performed between February 2011 and July 2013, subsequently submitted to surgery, whose histopathological reports were available in the internal information system. Biopsy results were compared with those observed at surgery and the underestimation rate was calculated by means of specific mathematical equations. Results: The underestimation rate at CNB was 50% for ADH and 28.57% for DCIS, and at VABB it was 25% for ADH and 14.28% for DCIS. ADH represented 10.25% of all cases undergoing biopsy, whereas DCIS accounted for 23.91%. Conclusion: The diagnostic underestimation rate at CNB is two times the rate at VABB. Certainty that the target has been achieved is not the sole determining factor for a reliable diagnosis. Removal of more than 50% of the target lesion should further reduce the risk of underestimation.

Resumo Objetivo: Determinar o grau de subestimação diagnóstica de biópsias mamárias percutâneas estereotáxicas por agulha grossa (core biopsy) e assistidas a vácuo (mamotomia) em lesões não palpáveis, com resultados histopatológico de hiperplasia ductal atípica (HDA) ou carcinoma ductal in situ (CDIS) e que foram submetidas a exérese cirúrgica posteriormente. Como objetivo secundário, atribuiu-se a frequência de HDA e CDIS nos casos biopsiados. Materiais e Métodos: Foram revisados, retrospectivamente, 40 casos biopsiados com diagnóstico de HDA ou CDIS, entre fevereiro de 2011 e julho de 2013, e que posteriormente foram submetidos a cirurgia, cujo laudo histopatológico estava registrado no sistema interno de informações. Os resultados das biópsias foram comparados aos da cirurgia e a taxa de subestimação foi calculada de acordo com equações matemáticas específicas. Resultados: A taxa de subestimação diagnóstica da core biopsy foi 50% para HDA e 28,57% para CDIS, e da mamotomia foi 25% para HDA e 14,28% para CDIS. As HDAs representaram 10,25% do total de casos biopsiados, enquanto 23,91% foram CDIS. Conclusão: A taxa de subestimação diagnóstica é cerca de duas vezes maior na core biopsy em relação à mamotomia. A certeza do alvo atingido não é o único determinante para um diagnóstico preciso. Remover mais que 50% da lesão alvo poderá diminuir o risco de subestimação diagnóstica.

Biopsias mamarias bajo resonancia magnética, experiencia preliminar / Breast biopsies performed under MRI, preliminary experience

La resonancia magnética (RM) mamaria se está convirtiendo en una herramienta de trabajo frecuentemente utilizada en nuestro medio. Existe un grupo de lesiones que sólo pueden ser identificadas por esta técnica, RMI only. Entre 14 a 20 por ciento de ellas serán malignas, según las diferentes series publicadas. Este tipo de lesiones requieren de biopsia guiada bajo RM. Pacientes y Métodos: se realizó revisión retrospectiva descriptiva de las biopsias asistidas por vacío realizadas en nuestra institución (período entre agosto de 2008 y junio de 2013). Resultados: El 0,3 por ciento (11) de las biopsias realizadas en nuestra institución fueron realizadas bajo RM, en 9 mujeres. En el 55 por ciento de los casos la indicación de la resonancia en la que se detectó la lesión biopsiada, fue etapificación de cáncer mamario recientemente diagnosticado; en el 100 porciento de los casos se realizó ultrasonido de segunda mirada, las lesiones tenían un tamaño promedio de 15 mm (4-29), un 63,6 por ciento fueron nódulos y el resto captaciones tipo no masa. La duración de la biopsia varió entre 40 y 130 minutos, un 27,2 por ciento resultaron lesiones malignas; 36,4 por ciento lesiones de alto riesgo; y 36,4 por ciento benignas. En el 45,5 por ciento el resultado de la biopsia bajo resonancia cambia la conducta quirúrgica. De las 7 lesiones operadas hubo subestimación en un caso de cáncer ductal in situ, que resultó cáncer ductal infiltrante. En el resto la histología quirúrgica fue idéntica a la de la biopsia bajo resonancia. Conclusión: Las biopsias bajo resonancia son infrecuentes, consumen un tiempo considerable, su correlación histológica es muy confiable y cambia la conducta quirúrgica casi en la mitad de los casos, lo cual tiene implicancias en el pronóstico de la paciente.

Abstract. Breast MRI is becoming a frequently used working tool in our environment. A group of lesions exist that can only be identified by this technique, "MRI only". Between 14-20 % of these will be malignant, according to various published series. Such lesions require biopsy guided under MRI. Patients and Methods: A descriptive retrospective review of vacuum-assisted biopsies was performed at our institution (period between August 2008 and June 2013). Results: 0.3 % (11) of the biopsies performed at our institution were done so under MRI, in 9 women. In 55% of the cases the resonance indication in which the biopsied lesion was detected, was newly diagnosed staging of breast cancer; in 100% of the cases a second-look ultrasound was performed, the lesions had an average size of 15 mm (4-29), 63.6% were nodules and the remainder other non-mass type deposits. The duration of the biopsy varied between 40 and 130 min, 27.2% were malignant lesions, 36.4 % high-risk lesions, and 36.4 % benign. In 45.5% the result of the biopsy performed under MRI changed the surgical procedure. Of the 7 operated lesions there was an underestimation in one case of ductal carcinoma in situ, which resulted being invasive ductal carcinoma. In the remainder, the surgical histology was identical to that of the biopsy performed under magnetic resonance. Conclusion: Biopsies performed under MRI are infrequent, they take considerable time, their histological correlation is very reliable and it changes the surgical procedure in almost half of the cases, which has implications in the prognosis of the patient.

Avaliação de um dispositivo portátil para biópsia vácuo-assistida de microcalcificações mamárias / Evaluation of a portable device for vacuum-assisted biopsy of breast microcalcifications

OBJETIVO: A biópsia vácuo-assistida é a forma percutânea de biópsia de microcalcificações que obtém a menor taxa de subestimação, porém, seu custo é alto, havendo interesse em se conseguir formas mais baratas de biópsia vácuo-assistida. O objetivo deste trabalho foi testar um dispositivo portátil de biópsia vácuo-assistida que apresenta custo menor. MATERIAIS E MÉTODOS: Foram biopsiadas 35 pacientes que apresentavam agrupamentos de microcalcificações BI-RADS® 4 ou 5. Foram testados a representatividade dos fragmentos colhidos, as dificuldades na reintrodução da cânula e o número de ciclos de colheita. RESULTADOS: Houve obtenção de calcificações representativas em todas as pacientes. Não houve discordância anatomorradiológica, dificuldade na reintrodução da cânula ou complicações graves. CONCLUSÃO: Os dados permitem concluir que o sistema apresenta boa eficácia na obtenção das amostras e com relação de custo-benefício favorável em relação a outros sistemas para a biópsia de microcalcificações, achados em concordância com outras publicações da literatura.

OBJECTIVE: Vacuum-assisted biopsy is the percutaneous technique of breast biopsy with the lowest underestimation rate. However, the cost of such procedure is high and currently there is a considerable interest in developing less expensive techniques. The present study was aimed at testing a less expensive device for vacuum-assisted biopsy of breast microcalcifications. MATERIALS AND METHODS: Thirty-five patients with clustered microcalcifications classified as BI-RADS® 4 or 5 were submitted to biopsy. Collected specimen appropriateness, difficulties in the reinsertion of the cannula and number of biopsy passes were evaluated. RESULTS: Successful specimens collection was achieved in all of the patients. Histo-radiological disagreement, difficulties in the cannula reinsertion or severe complications were not observed. CONCLUSION: The authors conclude that the method is effective in terms of specimens appropriateness and cost-benefit ratio as compared with of biopsy techniques for breast microcalcifications. Such findings are compatible with data reported in the literature.